Reproducibility of the three-dimensional endoscopic staging system for nasal polyposis

Sousa, Marcelo Castro Alves de; Becker, Helena Maria Gonçalves; Becker, Celso Gonçalves; Castro, Mirian Cabral Moreira de; Sousa, Nicodemos José Alves de; Guimarães, Roberto Eustáquio dos Santos

doi:10.1016/s1808-8694(15)30542-5

Cited by 6 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 We observed that the advanced staging (>14) in the patients studied led to a less significant response to the treatment regarding subjective improvement and reduction of staging, which differed from the results found by Suzuki et al 25 The present findings also differed from those of Videler et al , 16 in which the absence of a response found by the investigators after azithromycin could be justified by the advanced staging of the studied patients.…”

Section: Discussioncontrasting

confidence: 97%

“…The ENP diagnosis was based on the clinical history, nasal endoscopy, computed tomography, and biopsy of the nasal polyp according to criteria from the European Position Paper on Rhinosinusitis and Nasal Polyps 2012. 10 The research began with a complete otolaryngologic evaluation, ENP staging, 11 and biopsy of the polyps. After anesthesia of the nasal cavity with cotton soaked in 2% neotutocaine, poly with 5 ϫ 2 mm was removed by using EX-PLORENT (Olympus America Inc., Center Valley, PA) forceps, avoiding maceration of the tissue.…”

Section: General Designmentioning

confidence: 99%

“…The method consists of three-dimensional staging that has the advantage of identifying the location of the polyps in the three spatial planes and that classifies polyps that are in regions other than the middle meatus (Table 1). 11 The method is based only on the nasal endoscopy (nasofibroscopy). Each nasal cavity is staged separately.…”

Section: Variables Analyzedmentioning

confidence: 99%

See 2 more Smart Citations

Azithromycin for the Treatment of Eosinophilic Nasal Polyposis: Clinical and Histologic Analysis

Oliveira

Crosara²,

Cassali

et al. 2016

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 97%

Section: General Designmentioning

confidence: 99%

Section: Variables Analyzedmentioning

confidence: 99%

See 1 more Smart Citation

Azithromycin for the Treatment of Eosinophilic Nasal Polyposis: Clinical and Histologic Analysis

Oliveira

Crosara²,

Cassali

et al. 2016

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

show abstract

“…Increased scores have been associated with more symptoms and the presence of nasal polyps 40,45 and the same was found in our co-hort. To assess disease severity, 3-or 4-point scales have often been used with good inter-observer consistency in the practice of rhinology 46 . These scales are simple to apply and easy to compare in different studies.…”

Section: Discussionmentioning

confidence: 99%

The potential role of peak nasal inspiratory flow to evaluate active sinonasal inflammation and disease severity

Araújo-Martins

Brás-Geraldes

Neuparth

2020

Sci Rep

View full text Add to dashboard Cite

Although the pathophysiology of nasal polyposis is incompletely understood, rhinologists have seldom studied it with rhinomanometry or peak nasal inspiratory flow (PNIF) due to technical limitations and the perception that polyp size might impair reproducibility and the usefulness of recordings. The objective of this study is to assess how measures of rhinomanometry and PNIF relate to disease activity. Nineteen patients with polyps, 15 patients with chronic sinusitis without polyps and 11 negative controls were evaluated with active anterior rhinomanometry and PNIF. Sinusitis and polyp patients were re-evaluated after medical treatment. Polyp patients had the highest median Lund-Mackay score (14) and a median Johansen score of 1. PNIF and its variation after treatment were also lowest in this group (median 90 L/min before and after treatment; median variation of 0 L/min). Nasal resistance was similar between groups, and only correlated with Johansen score (Spearman = 0.517, p = 0.048) after treatment. Our study suggests that evaluating polyp patients using rhinomanometry and PNIF may provide useful and reproducible data. Several findings considered together suggest that polyp size is not the main determinant of nasal functional changes in these patients, warranting further studies to verify whether PNIF changes reflect sinus inflammation or merely airway obstruction.

show abstract

“…The present study evaluated the effect of azithromycin in a homogeneous group of patients with CRSwNP with asthma and aspirin intolerance in comparison with a placebo. Comparisons were also performed to evaluate changes in the scores on the Sino-Nasal Outcome Test (SNOT-22), changes in the staging of polyposis (16,17) , inflammatory infiltration (18) , and the eosinophil count between pretreatment and posttreatment. Additionally, patients were followed up for 1 year after the intervention and re-examined with the SNOT-22.…”

Section: Introductionmentioning

confidence: 99%

Azithromycin for chronic eosinophilic rhinosinusitis with nasal polyp: a placebo-controlled trial

Oliveira

Guimaraes

Pêgas

et al. 2020

Rhin

View full text Add to dashboard Cite

BACKGROUND: Chronic eosinophilic rhinosinusitis with nasal polyps (CRSwNP eosinophilic) is characterised by the formation of benign and bilateral nasal polyps. We aimed to compare the effectiveness of azithromycin as an immunomodulator with the use of a placebo in patients presenting with CRSwNP concomitant with asthma and aspirin intolerance after 3 months of treatment and at a 1-year follow-up. METHODOLOGY: We performed a randomised, double-blind, placebo-controlled trial. Patients received 500 mg azithromycin orally three times/week for 12 weeks. Improvement was evaluated by staging, the Sino-Nasal Outcome Test (SNOT-22), and nasal polyp biopsy. Data collected at pretreatment and 3 months posttreatment were compared. Quality of life was evaluated at the 1-year follow-up. RESULTS: Twenty-seven and 21 patients were treated with azithromycin and a placebo, respectively. The medication was well tolerated overall. Twenty patients (74%) in the azithromycin group and three patients (14%) in the placebo group were not refer- red for surgery at the end of the 3-month treatment. Regarding subjective improvement, there was a median decrease only in the azithromycin group, and the between-group difference was significant. SNOT-22 improvement was maintained in the azithromy- cin group at the 1-year follow-up. CONCLUSIONS: Azithromycin could be considered a therapeutic option for patients presenting with CRSwNP concomitant with asthma and aspirin intolerance.

show abstract

Reproducibility of the three-dimensional endoscopic staging system for nasal polyposis

Cited by 6 publications

References 19 publications

Azithromycin for the Treatment of Eosinophilic Nasal Polyposis: Clinical and Histologic Analysis

Azithromycin for the Treatment of Eosinophilic Nasal Polyposis: Clinical and Histologic Analysis

The potential role of peak nasal inspiratory flow to evaluate active sinonasal inflammation and disease severity

Azithromycin for chronic eosinophilic rhinosinusitis with nasal polyp: a placebo-controlled trial

Contact Info

Product

Resources

About